Search results: Sage Journals

Restricted accessReview articleFirst published 2025

Lutetium Lu 177 vipivotide tetraxetan: A literature review

Grace Morrison, Lisa M Holle

Journal of Oncology Pharmacy Practice

Restricted accessResearch articleFirst published October, 2003

Tyr 3 -Octreotide and Tyr 3 -Octreotate Radiolabeled with 177 Lu or 90 Y: Peptide Receptor Radionuclide Therapy Results In Vitro

Astrid Capello, Eric P. Krenning, Wout A.P. Breeman [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published June, 2011

Preparation of Patient Doses of 177 Lu-DOTA-TATE Using Indigenously Produced 177 Lu: The Indian Experience

Tapas Das, Sudipta Chakraborty, Kumar G. Kallur [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published June, 2007

Results of Individual Patient Dosimetry in Peptide Receptor Radionuclide Therapy with 177 Lu DOTA-TATE and 177 Lu DOTA-NOC

Christiane Wehrmann, Stefan Senftleben, Carolin Zachert [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published April, 2022

Estimation of Absorbed Doses of Indigenously Produced “Direct-route” Lutetium-177-[ 177 Lu]Lu-DOTA-TATE PRRT in Normal Organs and Tumor Lesions in Patients of Metastatic Neuroendocrine Tumors: Comparison with No-Carrier-Added [ 177 Lu]Lu-DOTA-TATE and the Trend with Multiple Cycles

Kamaldeep, Gaurav Wanage, Sarvesh Loharkar [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published April, 2003

Three-Dimensional Dose Model for the Comparison of 177 Lu-HuCC49ΔCH2 and 177 Lu-HuCC49 Radioimunotherapy in Mice Bearing Intraperitoneal Xenografts

Peter L. Roberson, Shigeru Yokoyama, Buck E. Rogers [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published August, 1957

Effect of Specific Activity on Distribution of Radiolutecium (Lu 177 ). ∗

William M. Christopherson, Granvil C. Kyker, H. F. Berg [...]

Experimental Biology and Medicine

Restricted accessResearch articleFirst published April, 2025

Generalized Seizure as an Acute post-[ 177 Lu]Lu-DOTATATE Side Effect in a Case of Recurrent Meningioma

Abdolmajid Alipour, Tahereh Ghaedian, Abbas Rakhsha [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published June, 2022

Clinical Dose Preparation of [ 177 Lu]Lu-DOTA-Pertuzumab Using Medium Specific Activity [ 177 Lu]LuCl 3 for Radioimmunotherapy of Breast and Epithelial Ovarian Cancers,with HER2 Receptor Overexpression

Sreeja Raj Menon, Arpit Mitra, Avik Chakraborty [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published December, 2010

Development of a 177 Lu-Labeled RGD Derivative for Targeting Angiogenesis

Chang Hwan Ju, Jae Min Jeong, Yun-Sang Lee [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessReview articleFirst published 2025

Lutetium Lu 177 vipivotide tetraxetan: A literature review

Grace Morrison, Lisa M Holle

Journal of Oncology Pharmacy Practice

Restricted accessResearch articleFirst published October, 2003

Tyr 3 -Octreotide and Tyr 3 -Octreotate Radiolabeled with 177 Lu or 90 Y: Peptide Receptor Radionuclide Therapy Results In Vitro

Astrid Capello, Eric P. Krenning, Wout A.P. Breeman [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published June, 2011

Preparation of Patient Doses of 177 Lu-DOTA-TATE Using Indigenously Produced 177 Lu: The Indian Experience

Tapas Das, Sudipta Chakraborty, Kumar G. Kallur [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published June, 2007

Results of Individual Patient Dosimetry in Peptide Receptor Radionuclide Therapy with 177 Lu DOTA-TATE and 177 Lu DOTA-NOC

Christiane Wehrmann, Stefan Senftleben, Carolin Zachert [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published April, 2022

Estimation of Absorbed Doses of Indigenously Produced “Direct-route” Lutetium-177-[ 177 Lu]Lu-DOTA-TATE PRRT in Normal Organs and Tumor Lesions in Patients of Metastatic Neuroendocrine Tumors: Comparison with No-Carrier-Added [ 177 Lu]Lu-DOTA-TATE and the Trend with Multiple Cycles

Kamaldeep, Gaurav Wanage, Sarvesh Loharkar [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published April, 2003

Three-Dimensional Dose Model for the Comparison of 177 Lu-HuCC49ΔCH2 and 177 Lu-HuCC49 Radioimunotherapy in Mice Bearing Intraperitoneal Xenografts

Peter L. Roberson, Shigeru Yokoyama, Buck E. Rogers [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published August, 1957

Effect of Specific Activity on Distribution of Radiolutecium (Lu 177 ). ∗

William M. Christopherson, Granvil C. Kyker, H. F. Berg [...]

Experimental Biology and Medicine

Restricted accessResearch articleFirst published April, 2025

Generalized Seizure as an Acute post-[ 177 Lu]Lu-DOTATATE Side Effect in a Case of Recurrent Meningioma

Abdolmajid Alipour, Tahereh Ghaedian, Abbas Rakhsha [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published June, 2022

Clinical Dose Preparation of [ 177 Lu]Lu-DOTA-Pertuzumab Using Medium Specific Activity [ 177 Lu]LuCl 3 for Radioimmunotherapy of Breast and Epithelial Ovarian Cancers,with HER2 Receptor Overexpression

Sreeja Raj Menon, Arpit Mitra, Avik Chakraborty [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published December, 2010

Development of a 177 Lu-Labeled RGD Derivative for Targeting Angiogenesis

Chang Hwan Ju, Jae Min Jeong, Yun-Sang Lee [...]

Cancer Biotherapy and Radiopharmaceuticals